![Jean-Louis Escary](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jean-Louis Escary
Nessuna posizione attualmente
Storia della carriera di Jean-Louis Escary
Precedenti posizioni note di Jean-Louis Escary
Società | Posizione | Inizio | Fine |
---|---|---|---|
POLTREG S.A. | Corporate Officer/Principal | - | 21/02/2024 |
GenOdyssee SA
![]() GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Presidente | 01/10/1999 | 11/05/2011 |
Fondatore | 18/12/2009 | 11/05/2011 | |
Presidente | 01/10/1999 | 11/05/2011 |
Formazione di Jean-Louis Escary
Statistiche
Distribuzione geografica
Francia | 3 |
Polonia | 2 |
Posizioni
Chairman | 1 |
Founder | 1 |
President | 1 |
Settori
Commercial Services | 2 |
Consumer Services | 2 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
POLTREG S.A. | Health Services |
Aziende private | 2 |
---|---|
GenOdyssee SA
![]() GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Commercial Services |
Université Pierre et Marie Curie | Consumer Services |
- Borsa valori
- Insiders
- Jean-Louis Escary
- Esperienza